PROVIDER PROFILE · NPI 1093221731

Elisabeth Dady

MEDICARE UTILIZATION · PART B · 2024

No data available for this provider in 2024.

PRESCRIBING · PART D · 2024

Total Rx claims

Beneficiaries

—

Total drug cost

$253

Distinct drugs

Brand share

45.8%

Top prescribed drugs

Cefdinir11 claims

QUALITY · MIPS · 2024

Final MIPS score

60.6

Quality

51.7

Cost

0.0

Improvement activities

40.0

Promoting interop.

0.0

Payment adjustment

-1.72%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$14

Payment records

By payment type

Food and Beverage$14

FACILITY AFFILIATIONS

Hospital & Facility Affiliations (1)

Hospital

CROSS-REFERENCE